SCHEMBL931631

SCHEMBL931631

COc1c(C)cc(Br)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
KDM4E B2RXH2 2/20 0.40
PKM P14618 1/20 0.40
MAPT P10636 4/20 0.39
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 2/20 0.36
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
TPMT P51580 1/20 0.35
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
TAS1R2 Q8TE23 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ACLY P53396 1/20 0.34
NMT1 P30419 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL442742 0.86 ALDH1A1 (0.44) POLBKDM4EMAPTALDH1A1GAA
SCHEMBL363341 0.84 KDM4E (0.45) KDM4EPKMMAPTALDH1A1GAA
SCHEMBL13256220 0.82 ACHE (0.46) POLBKDM4EMAPTALDH1A1GAA
Hydrochloric Acid SCHEMBL28586799 0.81 KDM4E (0.44) KDM4EPKMMAPTALDH1A1GAA
SCHEMBL4735982 0.81 KDM4E (0.44) KDM4EPKMMAPTALDH1A1GAA
SCHEMBL31533184 0.79 POLB (0.43) POLBKDM4EMAPTALDH1A1L3MBTL1
SCHEMBL10510118 0.77 MAPT (0.50) POLBKDM4EMAPTALDH1A1HSD17B10
SCHEMBL11216824 0.77 HSD17B10 (0.52) KDM4EPKMMAPTALDH1A1GAA
SCHEMBL21823580 0.77 TPMT (0.55) POLBKDM4EMAPTALDH1A1GAA
SCHEMBL20523636 0.77 GAA (0.41) POLBKDM4EMAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 ELEXOPHARM GMBH (DE) 2016-11-03 US disclosed
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 ELEXOPHARM GMBH (DE) 2016-11-03 US disclosed
WO-2011002409-A1 5H-PYRROLO[3,4-£>]PYRAZIN-7-AMINE DERIVATIVES INHIBITORS OF BETA-SECRETASE ASTRAZENECA AB (SE) 2011-01-06 WO disclosed
WO-2011002409-A1 5H-PYRROLO[3,4-£>]PYRAZIN-7-AMINE DERIVATIVES INHIBITORS OF BETA-SECRETASE ASTRAZENECA AB (SE) 2011-01-06 WO disclosed
US-4977178-A Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1990-12-11 US disclosed
US-4879391-A 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents PFIZER INC. (US) 1989-11-07 US disclosed
US-4861880-A 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1989-08-29 US disclosed
EP-0104860-B1 1-PHENYL-2(1H,3H)-INDOLONE PSYCHO-THERAPEUTIC AGENTS PFIZER INC. (US) 1987-03-18 EP disclosed
US-4476307-A Heteroylidene indolone compounds PFIZER INC. (US) 1984-10-09 US disclosed
EP-0104860-A1 1-Phenyl-2(1H,3H)-indolone psycho-therapeutic agents PFIZER INC. (US) 1984-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318895-A1 Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 HSD17B1, HSD17B2, HSD17B3 POLB 926/4885KDM4E 3647/4885PKM 3079/4885
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 POLB 3068/4885KDM4E 3923/4885PKM 2442/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 POLB 3068/4885KDM4E 3923/4885PKM 2442/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 POLB 3068/4885KDM4E 3923/4885PKM 2442/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH POLB 2983/4885KDM4E 2913/4885PKM 4045/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 POLB 2579/4885KDM4E 4178/4885PKM 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.